ClinicalTrials.gg
RecruitingNCT07634770Updated Jun 9, 2026

Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin

A Phase 1 interventional study of oral insulin and Placebo A in Diabetes Mellitus, Type 1, sponsored by Sam Chun Dang Pharm. Co. Ltd.. Recruiting at 1 site in Germany. Open to male participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Sam Chun Dang Pharm. Co. Ltd. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing insulin in Diabetes Mellitus, Type 1 — 4 open to participants now, 4 under way, none of them phase 3. Insulin · Diabetes Mellitus, Type 1.

Planned enrollment
33rd of 51
16 · median 20
Started
2026
with 1 other
Phase 1
4 of 51
1 open now
Registered
51st of 51
by date

Among the 51 studies testing insulin in Diabetes Mellitus, Type 1, this one is the 33rd largest by planned enrollment, is one of 2 that started in 2026, is one of 4 in phase 1, and was the 51st registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

4 of the 51 studies testing insulin in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 64 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing insulin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Reason for the study The participants have been diagnosed with type 1 diabetes and are being treated with standard insulin therapy.

The sponsor of the study is developing a new insulin-based medicine that can be taken by mouth (orally). For this reason, the investigational product named SCD0503 is to be tested in the study. The sponsor wants to investigate the course of blood concentrations and the blood sugar-lowering effect of the investigational product and to find out whether SCD0503 is safe.

Investigational product tested in this study The investigational product tested, SCD0503, is still under clinical evaluation and has not yet been approved for your treatment. The active ingredient is regular human insulin, which has been used for many years in approved medicines for the treatment of diabetes. SCD0503 is being used in humans for the first time in this study.

Study procedures The study will last for approximately 1 to 4 months. During this time, the participant will come to the investigational site 8 times for visits.

During 4 visits the participant will undergo a clamp examination. The blood sugar-lowering effect of the investigational product is determined using a clamp device, a computer-controlled device that maintains blood sugar at a constant level within the normal range. This is achieved by infusing a sugar solution. During 2 further visits the participant will have a meal test. During the meal test, the blood sugar-lowering effect of the investigational product is determined after intake of a standardized meal as breakfast. You will have catheters in your arms to take blood, measure your blood sugar level and to infuse glucose (sugar) or insulin, if needed.

SCD0503 is compared with a regular human insulin already approved for the treatment of diabetes.

The participant will receive SCD0503 and the comparator product during different visits to the investigational site. The participant will also receive a placebo together with the investigational or the comparator product. The placebo looks identical but contains no active ingredient. As the investigational product is administered orally and the comparator product is injected under the skin, two placebos are used in this study.

The order of medications given will be decided by chance, using a pre-defined method called randomization (a procedure similar to flipping a coin). Neither the participant nor the study physician will know which of the 2 medicines is administered at the respective dosing occasion. However, in case of emergency, this information will be quickly available.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male person with type 1 diabetes mellitus
  • Age between 18 and 64 years, both inclusive
  • (BMI) between 18.5 and 29.9 kg/m2, both inclusive
  • ≤ 8.5%
  • Fasting C-peptide \<= 0.20 nmol/L
  • Total insulin dose of \<1.2 (I)U/kg/day
  • Diabetes duration of at least 12 months at the time of screening
  • Stable insulin regimen for at least 2 months prior to inclusion into the trial

Exclusion criteria

Exclusion Criteria:

  • Systolic blood pressure \< 90 mmHg or >139 mmHg and/or diastolic blood pressure \< 50 mmHg or > 89 mmHg
  • Heart rate at rest outside the range of 50- 90 beats per minute
  • abnormal standard 12-lead (ECG) after 5 minutes resting in supine position at screening
  • Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (\<1 year) ophthalmologic examination
  • Peripheral neuropathy
  • More than one episode of severe hypoglycaemia with seizure, coma or requiring assistance of another person during the past 6 months pior to screening
  • Hospitalisation for diabetic ketoacidosis during the previous 6 months prior to screening
  • Significant history of alcoholism or drug abuse
  • Smoking more than 5 cigarettes or the equivalent per day
  • Tested positive for hepatitis Bs antigen
  • Tested positive for antibodies
  • Positive result to the test for -1/2 antibodies or HIV-1 antigen
  • Estimated (eGFR) \< 60.0 mL/min/1.73m2
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Sequence 1: SCD0503 low dose-SCD0503 medium dose-Actrapid-SCD0503 high dose-SCD0503 medium -Actrapid

    SCD0503 low dose: placebo B (subcutaneous injection)/ SCD0503 low dose + Placebo A medium dose (oral) SCD0503 medium dose: placebo B (subcutaneous injection)/ SCD0503 medium dose + Placebo A low dose (oral) SCD0503 high dose: placebo B (subcutaneous injection)/ SCD0503 high dose (oral) Actrapid: subcutaneous insulin/ Placebo A high dose (oral)

    Biological: oral insulin · Other: Placebo A · Biological: subcutaneous insulin · Other: Placebo B

  • Experimental
    Sequence 2: SCD0503 low dose-SCD0503 medium dose-Actrapid-SCD0503 high dose-Actrapid-SCD0503 medium

    Biological: oral insulin · Other: Placebo A · Biological: subcutaneous insulin · Other: Placebo B

  • Experimental
    Sequence 3: SCD0503 medium dose-SCD0503 high dose-SCD0503 low dose-Actrapid-SCD0503 medium-Actrapid

    Biological: oral insulin · Other: Placebo A · Biological: subcutaneous insulin · Other: Placebo B

  • Experimental
    Sequence 4: SCD0503 medium dose-SCD0503 high dose-SCD0503 low dose-Actrapid-Actrapid-SCD0503 medium

    Biological: oral insulin · Other: Placebo A · Biological: subcutaneous insulin · Other: Placebo B

  • Experimental
    Sequence 5: SCD0503 high dose-Actrapid-SCD0503 medium dose-SCD0503 low dose-SCD0503 medium-Actrapid

    Biological: oral insulin · Other: Placebo A · Biological: subcutaneous insulin · Other: Placebo B

  • Experimental
    Sequence 6: SCD0503 high dose-Actrapid-SCD0503 medium dose-SCD0503 low dose-Actrapid-SCD0503 medium

    Biological: oral insulin · Other: Placebo A · Biological: subcutaneous insulin · Other: Placebo B

  • Experimental
    Sequence 7: Actrapid-SCD0503 low dose-SCD0503 high dose-SCD0503 medium dose-SCD0503 medium-Actrapid

    Biological: oral insulin · Other: Placebo A · Biological: subcutaneous insulin · Other: Placebo B

  • Experimental
    Sequence 8: Actrapid-SCD0503 low dose-SCD0503 high dose-SCD0503 medium dose-Actrapid-SCD0503 medium

    Biological: oral insulin · Other: Placebo A · Biological: subcutaneous insulin · Other: Placebo B

Interventions

  • Biologicaloral insulin

    test product

    Also known as: SCD0503 low dose, SCD0503 medium dose, SCD0503 high dose

  • OtherPlacebo A

    placebo for test product

    Also known as: Placebo A low dose, Placebo A medium dose, Plaebo A high dose

  • reference product/comparator

    Also known as: Actrapid

  • OtherPlacebo B

    placebo for reference product

06

What researchers measure

Primary outcomes

  1. AUCins.0-6h, area under the serum insulin concentration curve from 0 to 6 hours

    Time frame: From enrollment to the end of treatment in 4 months

  2. Cins.max, maximum observed insulin concentration

    Time frame: From enrollment to the end of treatment in 4 months

  3. AUCGIR.0-6h, area under the insulin concentration-time curve from 0 to 6 hours

    Time frame: From enrollment to the end of treatment in 4 months

  4. GRELcl, Relative biopotency (will be derived of the dose corrected ratio of AUCGIR.0-6h for oral and sc insulin)

    Time frame: From enrollment to the end of treatment in 4 months

Secondary outcomes

  1. AUCins.0-1h, AUCins.0-2h, AUCins.0-4h, areas under the serum insulin concentration curve in the indicated time intervals

    Time frame: From enrollment to the end of treatment in 4 months

  2. tmax.ins., time to maximum observed insulin concentration

    Time frame: From enrollment to the end of treatment in 4 months

  3. λz, terminal elimination rate constant of insulin

    Time frame: From enrollment to the end of treatment in 4 months

  4. t½ is the terminal serum elimination half-life calculated as t½=ln2/λz

    Time frame: From enrollment to the end of treatment in 4 months

  5. MRT, Mean residence time (h)

    Time frame: From enrollment to the end of treatment in 4 months

  6. CL/F, Systemic clearance after oral administration (mL/min)

    Time frame: From enrollment to the end of treatment in 4 months

  7. V/F, volume of distribution (L)

    Time frame: From enrollment to the end of treatment in 4 months

  8. FRELcl, Relative bioavailability (will be derived from the dose corrected ratio of AUCins.0-6h for oral and sc insulin)

    Time frame: From enrollment to the end of treatment in 4 months

  9. Cins.max.fed, maximum observed insulin concentration after meal test

    Time frame: From enrollment to the end of treatment in 4 months

  10. AUCins.fed.0-1h, AUCins.fed.0-2h, AUCins.fed.0-4h, AUCins.fed.0-6h, areas under the serum insulin concentration curve in the indicated time intervals after meal test

    Time frame: From enrollment to the end of treatment in 4 months

  11. FRELfed, Relative bioavailability (will be derived of the dose corrected ratio of AUCins.fed.0-6 for oral and sc insulin)

    Time frame: From enrollment to the end of treatment in 4 months

  12. Food effect is investigated by comparing the total and maximum oral insulin exposure in the fasted state and after food intake

    Time frame: From enrollment to the end of treatment in 4 months

  13. AUCGIR.0-1h, AUCGIR.0-2h and AUCGIR.0-4h, areas under the glucose infusion rate curve in the indicated time-intervals

    Time frame: From enrollment to the end of treatment in 4 months

  14. GIRmax, maximum glucose infusion rate

    Time frame: From enrollment to the end of treatment in 4 months

  15. tmax.GIR., time to maximum glucose infusion rate

    Time frame: From enrollment to the end of treatment in 4 months

  16. t50%-GIR(early), time to half-maximum glucose infusion rate before GIRmax

    Time frame: From enrollment to the end of treatment in 4 months

  17. t50%-GIR(late), time to half-maximum glucose infusion rate after GIRmax

    Time frame: From enrollment to the end of treatment in 4 months

  18. Onset of action, time from trial product administration until plasma glucose concentration has decreased at least 5 mg/dL from baseline

    where baseline is defined as the mean of plasma glucose levels from -6, -4 and -2 minutes before trial product adminiadministration as measured by ClampArt

    Time frame: From enrollment to the end of treatment in 4 months

  19. PGmax, maximum plasma glucose after meal test

    Time frame: From enrollment to the end of treatment in 4 months

  20. AUCPG.0-1h, AUCPG.0-2h and AUCPG.0-4h and AUCPG.0-last areas under the plasma glucose concentration curve in the indicated time-intervals

    Time frame: From enrollment to the end of treatment in 4 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Oct 2026, 5 months after the start.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 5 months is below that.

Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 9, 2026
StartActual
May 29, 2026
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07634770
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
May 29, 2026
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jun 9, 2026

Study contacts

Clinical Manager
Contact
scd.global@scd.co.kr
please reach out by email

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion